Please login to the form below

Not currently logged in
Email:
Password:

No-deal

This page shows the latest No-deal news and features for those working in and with pharma, biotech and healthcare.

COVID-19 delays Pfizer, Mylan’s generics merger and spin-out

COVID-19 delays Pfizer, Mylan’s generics merger and spin-out

Meanwhile, Mylan's meeting of shareholders to approve the deal is also being moved back from 27 April to 30 June. ... There are no changes to the terms of the deal, which will see Pfizer acquire Mylan, merge it with Upjohn and spin out the combined

Latest news

More from news
Approximately 3 fully matching, plus 133 partially matching documents found.

Latest Intelligence

  • Case study: Leading by example Case study: Leading by example

    how the sector should respond publicly to the threat of a ‘no deal’ scenario. ... The company was keen to reassure patients about the steps it has taken to keep a continuity of medical supplies in a ‘no deal’ scenario.

  • The mission matters The mission matters

    No leader or leadership team has the technical knowledge to fully understand, let alone micromanage, such a diverse and expert group. ... No other industry has the same sort of bargain with society, which has been beneficial to both sides.

  • A snapshot of Crescendo Biologics A snapshot of Crescendo Biologics

    What impact will Brexit have on the business? The possibility of a no-deal Brexit and the weaker pound are not helpful for attracting key talent, especially from Europe. ... However, we continue to support our staff and are well prepared to deal with any

  • Building European biotech firms to rival those of the US Building European biotech firms to rival those of the US

    UK biotech can survive Brexit. There are enormous and well-founded concerns about the impact of a no-deal Brexit on the UK life sciences sector, and industry organisations such as ... No-one can be completely sure, but I can’t see why they wouldn’t

  • The new UK government-pharma industry pricing agreement – welcome news, but there are lessons to be learnt The new UK government-pharma industry pricing agreement – welcome news, but there are lessons to be learnt

    The deal is done. After undoubtedly tense negotiations, the heads of terms for the new Voluntary Scheme for Branded Medicines Pricing and Access have just been published, and although some among ... But these lofty ambitions were always that: just

More from intelligence
Approximately 0 fully matching, plus 26 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Wilmington Healthcare

A heritage to envy Wilmington Healthcare brings together the data intelligence specialisms of Binley’s, NHiS, Wellards and HSJ to create...

Latest intelligence

InSite Mapping™ - a Novel Tool for Insight-gathering and Patient Journey Mapping
Learn how a client engaged 18 rheumatologist advisors over 6 months to create a patient journey map for SLE....
Alone we can do so little, together we can do so much
Collaboration is at the heart of successful patient engagement and effective healthcare provision. But in such a complex, nuanced network, true collaborations are rare. So how can we, as an...
7 important considerations for creating an inclusive clinical trial website
You might have noticed that all of us here at COUCH Health are big advocates for taking action to improve diversity and inclusion in the world of clinical research. ‘Taking...

Infographics